You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Mere weeks after the 2019-nCoV sequence was released, firms, agencies, and research groups have already created PCR-based tests.
The Milwaukee, Wisconsin-based firm is part of a growing biotech ecosystem in the region, which has particular expertise in transplant medicine.
The startup is exploring options with potential partners and plans to bring a urinary tract infection test through regulatory channels in the next two years.
The firm has entered the market in Africa with a new collaboration in Ghana. It is also developing instrument-agnostic STI and liquid biopsy tests.
A study of the firm's tests to detect bacterial vaginosis, yeast infections, and trichomoniasis, show they can potentially improve treatment for women with vaginitis.
Microbiology lab and industry stakeholders are increasingly working together to coordinate approaches and generate more clinical utility data for diagnostic testing.
The method, dubbed GoPhAST-R, was codeveloped by researcher from the Broad Institute and NanoString, which now hopes to work with a partner to commercialize it.
The firm's tick-borne pathogens panel was also recently the subject of a clinical study, showing high accuracy in detecting numerous infectious agents.
The firm is also targeting a new market for oral fluid-based tests for drugs of abuse, projecting future growth due to new federal regulations.
A San Jose, California-based company appears to be the first in the US to routinely offer nanopore sequencing as part of a testing lab service.
An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.
The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.
CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.
In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.